This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ueda, Y.
Right arrow Articles by Sunagawa, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ueda, Y.
Right arrow Articles by Sunagawa, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2003, p. 2471-2480, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2471-2480.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vitro and In Vivo Activities of Novel 2-(Thiazol-2-ylthio)-1ß-Methylcarbapenems with Potent Activities against Multiresistant Gram-Positive Bacteria

Yutaka Ueda* and Makoto Sunagawa

Discovery Research Laboratories II, Sumitomo Pharmaceuticals Research Division, Konohana, Osaka 554-0022, Japan

Received 15 August 2002/ Returned for modification 17 February 2003/ Accepted 10 May 2003

SM-197436, SM-232721, and SM-232724 are new 1ß-methylcarbapenems with a unique 4-substituted thiazol-2-ylthio moiety at the C-2 side chain. In agar dilution susceptibility testing these novel carbapenems were active against methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis (MRSE) with a MIC90 of <=4 µg/ml. Furthermore, SM-232724 showed strong bactericidal activity against MRSA, in contrast to linezolid, which was bacteriostatic up to four times the MIC. SM-232724 showed good therapeutic efficacy comparable to those of vancomycin and linezolid against systemic infections of MRSA in cyclophosphamide-treated mice. The MICs of SM-197436, SM-232721, and SM-232724 for streptococci, including penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae strains, ranged from <=0.063 to 0.5 µg/ml. These drugs were the most active ß-lactams tested against Enterococcus faecium, and the MIC90 s for ampicillin-resistant E. faecium ranged between 8 and 16 µg/ml, which were slightly higher than the value for linezolid. However, time-kill assays revealed the superior bactericidal activity of SM-232724 compared to those of quinupristin-dalfopristin and linezolid against an E. faecium strain with a 4-log reduction in CFU at four times the MIC after 24 h of exposure to antibiotics. In addition, SM-232724 significantly reduced the numbers of bacteria in a murine abscess model with the E. faecium strain: its efficacy was superior to that of linezolid, although the MICs (2 µg/ml) of these two agents are the same. Among gram-negative bacteria, these three carbapenems were highly active against Haemophilus influenzae (including ampicillin-resistant strains), Moraxella catarrhalis, and Bacteroides fragilis, and showed antibacterial activity equivalent to that of imipenem for Escherichia coli, Klebsiella pneumoniae, and Proteus spp. Thus, these new carbapenems are promising candidates for agents to treat nosocomial bacterial infections by gram-positive and gram-negative bacteria, especially multiresistant gram-positive cocci, including MRSA and vancomycin-resistant enterococci.

* Corresponding author. Mailing address: Discovery Research Laboratories II, Sumitomo Pharmaceuticals Research Division, 3-1-98 Kasugade-naka, Konohana, Osaka 554-0022, Japan. Phone: (06) 6466-5271. Fax: (06) 6466-5491. E-mail: yutakau{at}sumitomopharm.co.jp.

Antimicrobial Agents and Chemotherapy, August 2003, p. 2471-2480, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2471-2480.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Koga, T., Masuda, N., Kakuta, M., Namba, E., Sugihara, C., Fukuoka, T. (2008). Potent In Vitro Activity of Tomopenem (CS-023) against Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52: 2849-2854 [Abstract] [Full Text]  
  • Ueda, Y., Kanazawa, K., Eguchi, K., Takemoto, K., Eriguchi, Y., Sunagawa, M. (2005). In Vitro and In Vivo Antibacterial Activities of SM-216601, a New Broad-Spectrum Parenteral Carbapenem. Antimicrob. Agents Chemother. 49: 4185-4196 [Abstract] [Full Text]  
  • Patel, M. V., De Souza, N. J., Gupte, S. V., Jafri, M. A., Bhagwat, S. S., Chugh, Y., Khorakiwala, H. F., Jacobs, M. R., Appelbaum, P. C. (2004). Antistaphylococcal Activity of WCK 771, a Tricyclic Fluoroquinolone, in Animal Infection Models. Antimicrob. Agents Chemother. 48: 4754-4761 [Abstract] [Full Text]  
  • Kurazono, M., Ida, T., Yamada, K., Hirai, Y., Maruyama, T., Shitara, E., Yonezawa, M. (2004). In Vitro Activities of ME1036 (CP5609), a Novel Parenteral Carbapenem, against Methicillin-Resistant Staphylococci. Antimicrob. Agents Chemother. 48: 2831-2837 [Abstract] [Full Text]  
  • Thomson, K. S., Moland, E. S. (2004). CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa. J Antimicrob Chemother 54: 557-562 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»